High-Risk Acute Myeloid Leukemia: A Pediatric Prospective

Pediatric acute myeloid leukemia is a clonal disorder characterized by malignant transformation of the hematopoietic stem cell. The incidence and the outcome remain inferior when compared to pediatric ALL, although prognosis has improved in the last decades, with 80% overall survival rate reported i...

Descripción completa

Detalles Bibliográficos
Autores principales: Cacace, Fabiana, Iula, Rossella, De Novellis, Danilo, Caprioli, Valeria, D’Amico, Maria Rosaria, De Simone, Giuseppina, Cuccurullo, Rosanna, Wierda, William G., Mahadeo, Kris Michael, Menna, Giuseppe, Tambaro, Francesco Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220202/
https://www.ncbi.nlm.nih.gov/pubmed/35740427
http://dx.doi.org/10.3390/biomedicines10061405
Descripción
Sumario:Pediatric acute myeloid leukemia is a clonal disorder characterized by malignant transformation of the hematopoietic stem cell. The incidence and the outcome remain inferior when compared to pediatric ALL, although prognosis has improved in the last decades, with 80% overall survival rate reported in some studies. The standard therapeutic approach is a combined cytarabine and anthracycline-based regimen followed by consolidation with allogeneic stem cell transplantation (allo-SCT) for high-risk AML and allo-SCT for non-high-risk patients only in second complete remission after relapse. In the last decade, several drugs have been used in clinical trials to improve outcomes in pediatric AML treatment.

Ejemplares similares